An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer

Modified interleukin-2 (IL-2) formulations are being tested in cancer patients. However, IL-2 immunotherapy damages IL-2 receptor (IL-2R)-positive endothelial cells and stimulates IL-2Rα (CD25)-expressing lymphocytes that curtail anti-tumor responses. A first generation of IL-2Rβ (CD122)-biased IL-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahin, Dilara, Arenas-Ramirez, Natalia, Rath, Matthias, Karakus, Ufuk, Hümbelin, Monika, van Gogh, Merel, Borsig, Lubor, Boyman, Onur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755894/
https://www.ncbi.nlm.nih.gov/pubmed/33353953
http://dx.doi.org/10.1038/s41467-020-20220-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755894/
https://www.ncbi.nlm.nih.gov/pubmed/33353953
http://dx.doi.org/10.1038/s41467-020-20220-1

Ejemplares similares